These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 18952618)

  • 1. Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis.
    Macías J; Orihuela F; Rivero A; Viciana P; Márquez M; Portilla J; Ríos MJ; Muñoz L; Pasquau J; Castaño MA; Abdel-Kader L; Pineda JA;
    J Antimicrob Chemother; 2009 Jan; 63(1):178-83. PubMed ID: 18952618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic profile analyses of tipranavir in Phase II and III clinical trials.
    Mikl J; Sulkowski MS; Benhamou Y; Dieterich D; Pol S; Rockstroh J; Robinson PA; Ranga M; Stern JO
    BMC Infect Dis; 2009 Dec; 9():203. PubMed ID: 20003457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
    Neukam K; Mira JA; Ruiz-Morales J; Rivero A; Collado A; Torres-Cornejo A; Merino D; de Los Santos-Gil I; Macías J; González-Serrano M; Camacho A; Parra-García G; Pineda JA;
    J Antimicrob Chemother; 2011 Nov; 66(11):2605-14. PubMed ID: 21903660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.
    Cahn P; Villacian J; Lazzarin A; Katlama C; Grinsztejn B; Arasteh K; López P; Clumeck N; Gerstoft J; Stavrianeas N; Moreno S; Antunes F; Neubacher D; Mayers D
    Clin Infect Dis; 2006 Nov; 43(10):1347-56. PubMed ID: 17051504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.
    Gathe J; Cooper DA; Farthing C; Jayaweera D; Norris D; Pierone G; Steinhart CR; Trottier B; Walmsley SL; Workman C; Mukwaya G; Kohlbrenner V; Dohnanyi C; McCallister S; Mayers D;
    Clin Infect Dis; 2006 Nov; 43(10):1337-46. PubMed ID: 17051503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.
    Pineda JA; Santos J; Rivero A; Abdel-Kader L; Palacios R; Camacho A; Lozano F; Macías J;
    J Antimicrob Chemother; 2008 Apr; 61(4):925-32. PubMed ID: 18276600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents.
    Salazar JC; Cahn P; Yogev R; Negra MD; Castelli-Gattinara G; Fortuny C; Flynn PM; Giaquinto C; Ruan PK; Smith ME; Mikl J; Jelaska A;
    AIDS; 2008 Sep; 22(14):1789-98. PubMed ID: 18753862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracranial hemorrhage and liver-associated deaths associated with tipranavir/ritonavir: review of cases from the FDA's Adverse Event Reporting System.
    Chan-Tack KM; Struble KA; Birnkrant DB
    AIDS Patient Care STDS; 2008 Nov; 22(11):843-50. PubMed ID: 19025478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with men.
    Walmsley SL; Squires K; Weiss L; Easterbrook P; Orani A; Kraft M; Scherer J
    AIDS; 2009 Jan; 23(3):429-31. PubMed ID: 19114862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients.
    Merchante N; López-Cortés LF; Delgado-Fernández M; Ríos-Villegas MJ; Márquez-Solero M; Merino D; Pasquau J; García-Figueras C; Martínez-Pérez MA; Omar M; Rivero A; Macías J; Mata R; Pineda JA;
    AIDS Patient Care STDS; 2011 Jul; 25(7):395-402. PubMed ID: 21688986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients.
    Gathe JC; Pierone G; Piliero P; Arasteh K; Rubio R; Lalonde RG; Cooper D; Lazzarin A; Kohlbrenner VM; Dohnanyi C; Sabo J; Mayers D
    AIDS Res Hum Retroviruses; 2007 Feb; 23(2):216-23. PubMed ID: 17263650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.
    Luna B; Townsend MU
    Clin Ther; 2007 Nov; 29(11):2309-18. PubMed ID: 18158073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term effect of ritonavir-boosted atazanavir in hepatitis B and/or C co-infected, treatment-experienced HIV patients.
    Pérez-Elías MJ; Gatell JM; Flores J; Santos J; Vera-Médez F; Clotet B; Moreno A; Pérez-Molina JA; Vendrell B; Serrano O
    HIV Clin Trials; 2009; 10(4):269-75. PubMed ID: 19723614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults.
    Carr A; Ritzhaupt A; Zhang W; Zajdenverg R; Workman C; Gatell JM; Cahn P; Chaves R
    AIDS; 2008 Nov; 22(17):2313-21. PubMed ID: 18981770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone.
    Bruce RD; Altice FL; Moody DE; Lin SN; Fang WB; Sabo JP; Wruck JM; Piliero PJ; Conner C; Andrews L; Friedland GH
    Drug Alcohol Depend; 2009 Dec; 105(3):234-9. PubMed ID: 19726139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials.
    Hill A; Moyle G
    HIV Med; 2007 May; 8(4):259-64. PubMed ID: 17461854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tipranavir in highly antiretroviral treatment-experienced patients: Results from a French prospective cohort.
    Allavena C; Flandre P; Pugliese P; Valantin MA; Poizot-Martin I; Cabié A; Melliez H; Cuzin L; Duvivier C; Dellamonica P; Raffi F;
    Scand J Infect Dis; 2012 Jan; 44(1):37-43. PubMed ID: 21851330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3.
    Rachlis A; Clotet B; Baxter J; Murphy R; Lefebvre E
    HIV Clin Trials; 2007; 8(4):213-20. PubMed ID: 17720661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
    Hicks CB; Cahn P; Cooper DA; Walmsley SL; Katlama C; Clotet B; Lazzarin A; Johnson MA; Neubacher D; Mayers D; Valdez H;
    Lancet; 2006 Aug; 368(9534):466-75. PubMed ID: 16890833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life and tolerability in treatment-experienced HIV-1-infected patients on tipranavir versus comparator regimens.
    Huang IC; Wu AW; Finnern HW; Thijs H; Gathe JC; Fairclough DL
    Antivir Ther; 2008; 13(1):15-25. PubMed ID: 18389895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.